ASH 2017 Conference Coverage
World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017.
- CAR T-Cell Therapy in Multiple Myeloma
- Novel Therapies Multiple Myeloma
- Newly Diagnosed Multiple Myeloma
- Relapsed and Refractory Multiple Myeloma
- Smoldering Multiple Myeloma
- Novel Administration of Daratumumab
Rafael Fonseca, MD discusses:
Abstract 904: Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide.
Abstract 401: Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study.
Xavier Leleu, MD discusses:
Abstract 398: First report of the IFM 2014-02 randomized open label phase 3 trial of 2 conditioning regimen, HDM 200 versus Bortezomib +HDM 200.
Abstract 739: Update of the POLLUX phase 3 randomized open label international trial of Daratumumab plus lenalidomide and dexamethasone, versus the doublet control arm lenalidomide and dexamethasone.
Ravi Vi, MD discusses:
Abstract 392: Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression.
Abstract 740: Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy.
Wee Joo Chng, MD discusses:
Abstract 839: Genomic Predictors of Progression-Free Survival Among Patients.with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial.
Abstract 436: Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial.
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.